Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on October 30, 2018. The filing reports significant corporate governance changes, specifically the expansion of the Board of Directors and the appointment of new leadership roles effective October 30, 2018.

Key Financial Metrics

The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and associated compensation arrangements.

Material Changes

  • Board Expansion: The Board size was increased to seven directors.
  • New Director Appointment: Thomas A. Schreck was appointed to fill the new vacancy. He will serve on the Audit Committee and chair both the Compensation Committee and the Nominating and Governance Committee.
  • Executive Chairman Appointment: Steven Sherman was appointed as Executive Chairman for an initial two-year term. He will advise the CEO on strategic business development and will step down from all Board committee memberships.

Compensation and Governance Details

Thomas A. Schreck (Director):

  • Annual retainer: $35,000.
  • Committee fees: $7,500 (Audit), $15,000 (Compensation Chair), $15,000 (Nominating Chair).
  • Equity: Option to purchase 30,750 shares, vesting in nine equal monthly installments starting November 30, 2018.

Steven Sherman (Executive Chairman):

  • Annual base salary: $100,000.
  • Equity: Recommended option to purchase 400,000 shares, vesting in eight equal quarterly installments starting January 30, 2019.

Risks and Contingencies: The filing states there are no undisclosed arrangements or family relationships influencing these appointments. No specific financial risks or contingencies are disclosed in this report.

Investor Verification Checklist

  • Verify the impact of the new Executive Chairman role on the company's strategic direction.
  • Confirm the vesting schedules and potential dilution from the 430,750 total new stock options granted.
  • Review the updated Board composition and committee structures for governance implications.
  • Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.